Clinical trial · Observational
Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients
Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients:an Open, Prospective,Non-randomized Phase III Clinical Trial
NCT03411954CI-TRIAL-00031393unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, non-randomized phase III study observing the cognitive function changes with conformal hippocampus avoidance during intensity modulated radiotherapy for T4 nasopharyngeal carcinoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- HP-RT
- description
- Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
Primary outcomes (1)
- measure
- the dose-volume relationship between hippocampus and cognitive function
- timeFrame
- 1 year
- description
- To explore the relationship between cognitive impairment and exposure dose of hippocampus in patients with nasopharyngeal carcinoma.
Secondary outcomes (3)
- measure
- cognitive function changes
- timeFrame
- 1 year
- description
- response to the Montreal Cognitive Assessment
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologic confirmed nasopharyngeal carcinoma 2. ECOG performance scale 0-2 3. Tumor stage is T4N0-3M0-1 according to 8th American Joint Commission on Cancer edition 4. Adequate hepatic, renal and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 100×10\^9/L, neutrophils ≥ 1.5×10\^9/L, serum transaminase \< 2.5×the upper limit of normal(ULN), (If liver metastases, serum transaminase\< 5×the ULN), creatinine clearance rate \> 60ml/min. 5. Informed consent signed. Exclusion Criteria: 1. History of malignant tumors. 2. Any severe complications contraindicated chemotherapy or radiotherapy. 3. Medical history of central nervous system, cognitive or psychological diseases; 4. Pregnant or nursing women. 5. Patients with mental disease cannot complete the questionaire. 6. MRI contraindication -
References
Publications (0)
Data not yet available
No reference posted for this study.